This aligns with prior research examining the association between ctDNA detection and prognosis in other breast cancer subtypes (e.g., HER2+ and triple-negative breast cancer) patients [59,60,61,62,63], as well as in other cancer types [64,65,66]. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.